Aktis Oncology, Inc. (AKTS)
Aktis Oncology, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.
Aktis Oncology, Inc. (AKTS) is a Biotechnology company based in US with a market capitalization of $1.1B. Free cash flow was negative at -$73.7M. This page tracks AKTS's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.
US · 79 employees · IPO Jan 9, 2026
Valuation
Valuation & price
$19.21as of May 15, 2026· -40.4% vs 52w high
—
P/E ratio
Latest-FY diluted EPS
—
P/B ratio
Market cap ÷ book equity
—
Dividend yield
Price — last 12 months
Fundamentals
Key fundamentals
$1.1B
Market cap
—
Revenue growth (YoY)
100.0%
Gross margin
-$73.7M
Free cash flow (USD)
-$215.2M
Net debt
Net cash position
50.6%
Share dilution
0/3
Graham criteria passed
Defensive-investor screen
Healthcare
Sector
Trajectory
Long-term trends
Revenue by year
2022 → 2025
Free cash flow by year
2022 → 2025
Gross margin by year
2024 → 2025
Value screen
Graham defensive-investor tests
0
Insider buys · 90 days
0
Insider sells · 90 days
Earnings
Last reported: Jun 3, 2026
Next expected: not yet scheduled
On the tape
Recent SEC & insider activity
Questions
Frequently asked questions
What is Aktis Oncology, Inc.'s market cap?
Aktis Oncology, Inc. (AKTS) has a market capitalization of $1.1B.
What is AKTS's P/E ratio?
A meaningful P/E ratio is not available for AKTS — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.
When did Aktis Oncology, Inc. last report earnings?
AKTS last reported earnings on June 3, 2026; the next date is not yet scheduled.
Are insiders buying AKTS stock?
SEC Form 4 filings show no open-market insider buys at Aktis Oncology, Inc. in the last 90 days (0 sells).
Same arena
Related companies in Biotechnology
Timeline
Every filing, insider trade & earnings on a price-anchored timeline
Filing Analyzer
Search the actual 10-K / 10-Q text with AI research angles
News
Latest press coverage in one feed
Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.